Seagen Looks To Revive Cancer Drug Claims In Daiichi Fight
U.S. biotech company Seagen Inc. will look to revive its claims seeking billions of dollars in damages in a dispute with Japanese drugmaker Daiichi Sankyo Co. Ltd. over cancer drug patents,...To view the full article, register now.
Already a subscriber? Click here to view full article